KR840008333A - 피리미딘 유도체의 제조방법 - Google Patents

피리미딘 유도체의 제조방법 Download PDF

Info

Publication number
KR840008333A
KR840008333A KR1019840001414A KR840001414A KR840008333A KR 840008333 A KR840008333 A KR 840008333A KR 1019840001414 A KR1019840001414 A KR 1019840001414A KR 840001414 A KR840001414 A KR 840001414A KR 840008333 A KR840008333 A KR 840008333A
Authority
KR
South Korea
Prior art keywords
formula
salt
compound
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019840001414A
Other languages
English (en)
Korean (ko)
Inventor
다까오 다까야 (외 2)
Original Assignee
후지사와 도모기찌로
후지사와 야꾸힝 고교 가부시기 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB838308290A external-priority patent/GB8308290D0/en
Priority claimed from GB838315542A external-priority patent/GB8315542D0/en
Priority claimed from GB838327859A external-priority patent/GB8327859D0/en
Application filed by 후지사와 도모기찌로, 후지사와 야꾸힝 고교 가부시기 가이샤 filed Critical 후지사와 도모기찌로
Publication of KR840008333A publication Critical patent/KR840008333A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1019840001414A 1983-03-25 1984-03-20 피리미딘 유도체의 제조방법 Ceased KR840008333A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB838308290A GB8308290D0 (en) 1983-03-25 1983-03-25 Pyrimidinone derivatives
GB8308290 1983-03-25
GB838315542A GB8315542D0 (en) 1983-06-07 1983-06-07 Pyrimidinone derivatives
GB8315542 1983-06-07
GB838327859A GB8327859D0 (en) 1983-10-18 1983-10-18 Pyrimidine derivatives
GB8327859 1983-10-18

Publications (1)

Publication Number Publication Date
KR840008333A true KR840008333A (ko) 1984-12-14

Family

ID=27262023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840001414A Ceased KR840008333A (ko) 1983-03-25 1984-03-20 피리미딘 유도체의 제조방법

Country Status (13)

Country Link
US (3) US4612376A (OSRAM)
EP (1) EP0123402B1 (OSRAM)
KR (1) KR840008333A (OSRAM)
CA (1) CA1256107A (OSRAM)
DE (1) DE3473875D1 (OSRAM)
DK (1) DK160492C (OSRAM)
ES (2) ES8505972A1 (OSRAM)
FI (1) FI841128A7 (OSRAM)
GR (1) GR81758B (OSRAM)
HU (1) HU195195B (OSRAM)
NO (1) NO841168L (OSRAM)
PH (1) PH22022A (OSRAM)
SU (2) SU1349698A3 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US4598149A (en) * 1984-03-02 1986-07-01 Merck & Co., Inc. 3-amino-2-hydroxypropyl of pyrimidin-4-one useful as antihypertensive, cardioprotective, antiarrythmic, and antianginal agents
US4649142A (en) * 1984-06-25 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. 3,4-dihydro-1,3-disubstituted-6-(substituted phenylimino)-2(1H)-pyrimidinone useful as cardiotonic agent and anti-allergic agent
US4708958A (en) * 1986-09-24 1987-11-24 G. D. Searle & Co. 6-(imidazolyphenyl)-4-iminopyrimidinones useful as hypotensive agents
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
IT1270122B (it) * 1994-10-04 1997-04-28 Ist Superiore Sanita 6-benzil-4-ossopirimidine sostituite, processo per la loro preparazione e composizioni farmaceutiche che le contengono
KR100453097B1 (ko) * 1995-09-06 2004-12-31 코와 가부시키가이샤 피리미딘유도체
US6244121B1 (en) * 1998-03-06 2001-06-12 Applied Materials, Inc. Sensor device for non-intrusive diagnosis of a semiconductor processing system
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
JP4920410B2 (ja) 2003-07-14 2012-04-18 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
DOP2006000009A (es) 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
CA2620065C (en) 2005-08-22 2011-03-29 Melior Discovery, Inc. Methods and formulations for modulating lyn kinase activity and treating related disorders
US20100152215A1 (en) * 2007-02-20 2010-06-17 Melior Pharmaceuticals I, Inc. Methods of identifying activators of lyn kinase
CA2693809A1 (en) * 2007-07-23 2009-01-29 Melior Discovery, Inc. Methods of activating irs-1 and akt
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
TWI393716B (zh) * 2009-08-04 2013-04-21 Merck Sharp & Dohme 作為ｉｘａ因子抑制劑之雜環化合物
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US10183949B2 (en) 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
WO2016031987A1 (ja) * 2014-08-29 2016-03-03 国立大学法人東京大学 オートタキシン阻害活性を有するピリミジノン誘導体
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3310760B8 (en) 2015-06-22 2022-10-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
EP3609500B1 (en) 2017-04-10 2024-11-13 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
CN109053589A (zh) * 2018-09-30 2018-12-21 浙江师范大学 4-亚胺基四氢嘧啶-2-酮类化合物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1296371A (OSRAM) * 1969-02-26 1972-11-15
AU1108070A (en) * 1969-03-06 1971-08-12 Imperial Chemical Industries Limited Pyrimidine derivatives
GB1336138A (en) * 1969-12-10 1973-11-07 Ici Ltd Process for the production of pyrimidine derivatives
US3923807A (en) * 1973-09-10 1975-12-02 Takeda Chemical Industries Ltd 6-Aminouracil derivatives
US4208366A (en) * 1978-10-31 1980-06-17 E. I. Du Pont De Nemours And Company Process for preparing a nonwoven web
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent

Also Published As

Publication number Publication date
DK160492B (da) 1991-03-18
ES530916A0 (es) 1985-06-16
ES538190A0 (es) 1985-11-01
EP0123402B1 (en) 1988-09-07
US4612376A (en) 1986-09-16
NO841168L (no) 1984-09-26
EP0123402A3 (en) 1985-09-18
DK166884A (da) 1984-09-26
DK166884D0 (da) 1984-03-23
DK160492C (da) 1991-08-26
DE3473875D1 (en) 1988-10-13
PH22022A (en) 1988-05-13
FI841128A7 (fi) 1984-09-26
US4746664A (en) 1988-05-24
US4824851A (en) 1989-04-25
GR81758B (OSRAM) 1984-12-12
ES8601922A1 (es) 1985-11-01
SU1436872A3 (ru) 1988-11-07
CA1256107A (en) 1989-06-20
EP0123402A2 (en) 1984-10-31
SU1349698A3 (ru) 1987-10-30
ES8505972A1 (es) 1985-06-16
FI841128A0 (fi) 1984-03-21
HU195195B (en) 1988-04-28

Similar Documents

Publication Publication Date Title
KR840008333A (ko) 피리미딘 유도체의 제조방법
KR840008016A (ko) 융합 이미다졸 화합물의 제조방법
KR870007163A (ko) 질소함유 융합 헤테로 사이클릭 화합물의 제조방법
KR840007879A (ko) 이미다조-헤테로싸이클 화합물의 제조방법
KR830007642A (ko) 7-아미노-1-사이클로프로필-4-옥소-1,4-디하이드로-나프티리딘-3-카복실산의 제조방법
KR880005127A (ko) 이미다조 피리딘 유도체 및 이의 제조방법
KR870001192A (ko) 신규한(4-치환-피페라진일) 피리다진류의 제조방법
KR860004032A (ko) 피페라진 화합물의 제조방법
KR830005216A (ko) 이미다조[4,5-b] 피리딘 유도체의 제조방법
KR850005829A (ko) 2-시아노벤즈이미다졸 유도체의 제조방법
KR840000563A (ko) 세펨 화합물의 제조방법
KR840002816A (ko) 이미다졸 또는 트리아졸 유도체, 이들의 산부가염 및 이들의 금속착염의 제조방법
KR860003259A (ko) 벤젠-융합 복소환 화합물의 제조방법
KR860003234A (ko) N-치환된 트리아졸 유도체의 제조방법
KR840004076A (ko) 티오메틸 파리딘 유도체의 제조방법
KR830007542A (ko) 아로일 아미노산 유도체의 제조방법
ATE116991T1 (de) Semisynthetische rhodomycine, verfahren zu ihrer herstellung und ihre verwendung als zytostatika.
KR830009069A (ko) 알카놀아민 유도체의 제조방법
KR860007250A (ko) 신규의 2-치환-4,6-디아미노-s-트리아진·이소시아 누르산 부가물의 합성 방법
KR840005107A (ko) 피리미디온 및 그의 산부가염의 제조방법
KR850001173A (ko) 2-치환된 4-페닐이미다졸 아미딘 유도체의 제조방법
KR860008148A (ko) 헤테로 사이클릭 아미드 유도체의 제조방법
KR870002110A (ko) 구아니디노티아졸 유도체의 제조방법
KR850001204A (ko) 1,4-디하이드로피리딘 유도체의 제조방법
KR860003204A (ko) 디페닐메틸이민 유도체의 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19840320

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19890125

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19840320

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19910104

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19910604

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19910104

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I